1 – 10 of 14
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
- Contribution to journal › Article
-
Mark
Combining plasma p-tau217 and cross-cultural cognitive tests to identify Alzheimer's Disease in an ethnically diverse mixed memory clinic cohort
- Contribution to journal › Article
-
Mark
Cell-weighted polygenic risk scores are associated with β-amyloid and tau biomarkers in Alzheimer's disease
- Contribution to journal › Article
-
Mark
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals : implications for clinical trials
- Contribution to journal › Article
-
Mark
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study
- Contribution to journal › Article
-
Mark
A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's disease
- Contribution to journal › Article
-
Mark
Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease : A consecutive mixed memory clinic cohort study
- Contribution to journal › Article
- 2024
-
Mark
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
- Contribution to journal › Article
- 2023
-
Mark
DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease
- Contribution to journal › Article
-
Mark
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
- Contribution to journal › Article
